ClinicalTrials.Veeva

Menu

Mandibular Advancement vs Home Treatment for Primary Snoring

The Washington University logo

The Washington University

Status and phase

Completed
Phase 2

Conditions

Snoring

Treatments

Combination Product: Conservative treatment Arm
Device: Interventional Arm

Study type

Interventional

Funder types

Other

Identifiers

NCT05756647
202208175

Details and patient eligibility

About

This is a randomized controlled trial for non-apneic snorers. The primary goal of the study is to evaluate the efficacy of a mandibular advancement device (MAD) vs conservative treatment for adults with non-apneic snoring as measured by the partners report of response to treatment (CGI-I). The secondary goal is to evaluate the effectiveness of treatment of snoring on the Epworth Sleepiness Scale (ESS), a modified Symptoms of Nocturnal Obstruction and Related Events (SNORE-25) questionnaire, the Pittsburgh Sleep Quality Index (PSQI), and the Clinical Global Impression of Severity Scale (CGI-S)

Full description

Snoring is a problem which affects roughly half of adults, but rigorous studies on how to treat isolated snoring have not been completed. Mandibular advancement devices (MAD) show consistent improvements in sleep quality for patients with sleep apnea; however, their effect on patients with primary snoring remains less well known.

The primary hypothesis proposes that adults with non-apneic snoring treated with a MAD will experience a greater reduction of snoring as measured by the Clinical Global Impression - Improvement (GCI-I) Scale response of the sleeping partner.

The plan is to enroll 30 participants and 30 sleeping partner participants for each arm of the trial: 120 participants, or 60 pairs, in total. Participants will use the intervention nightly for a period of 4 weeks after which an end of study visit will occur. All post intervention outcomes will be recorded at the end of the study visit. Knowledge gained from this study will help guide treatment practice and evidence-based approaches regarding non-apneic snoring.

Enrollment

100 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age ≥ 18
  • Report of snoring
  • Prior polysomnogram (PSG) within the past 60 months showing AHI (Apnea Hypopnea Index) < 5 and no more than 10% gain in body weight since the prior polysomnogram OR reasonable clinical suspicion that the participant does not have sleep apnea [Reasonable Clinical Suspicion is defined as: BMI <35, Neck circumference <16.5 inches, lack of uncontrolled hypertension, no witnessed episodes of apnea, or multiple sleep studies in the past all showing lack of sleep apnea but with >5 years since the most recent one.]
  • Possess a sleeping partner who sleeps in the same room as the participant for >= 4 nights a week and who can report outcomes
  • Access to the internet
  • Ability to follow up within 1 month after adequate fitting of MAD or 4 weeks of Mometasone

Inclusion criteria for the sleeping partner:

  • Age ≥ 18
  • Possess a sleeping partner who sleeps in the same room as the participant for >= 4 nights a week and who can report outcomes
  • Access to the internet

Exclusion criteria

Individuals will not be allowed to participate in this study if they meet one or more of the exclusion criteria:

  • Significant hypoxemia as defined as SaO2 (oxygen saturation) below 89% for ≥ 12% of the total nocturnal monitoring time
  • Inability to wear a MAD defined as missing more than 50% of their dentition or their dentition is not in good condition.
  • Prior intolerance of MAD
  • Current treatment for OSA
  • Concurrent use of sedatives or > 2 alcoholic drinks per night
  • Chronic nasal obstruction due to structural anatomic defects, nasal polyps, or history of unresponsiveness to nasal rinses.

Sleeping partners do not have any exclusion criteria defined for this study.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

100 participants in 2 patient groups

Interventional Arm
Experimental group
Description:
The Mandibular Advancement Device for this study will be the ProSomnus Sleep Device. It is a sleep device intended to reduce nighttime snoring and mild to moderate Obstructive Sleep Apnea in adults by holding the lower jaw forward during sleep
Treatment:
Device: Interventional Arm
Conservative treatment Arm
Active Comparator group
Description:
The conservative treatment will consist of four different interventions: Mometasone nasal rinse, External nasal dilatory therapy, Mouth taping and Lateral positional therapy.
Treatment:
Combination Product: Conservative treatment Arm

Trial documents
1

Trial contacts and locations

1

Loading...

Central trial contact

Sara Kukuljan; Jay F Piccirillo, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems